DBZ is a putative PPARÎ³ agonist that prevents high fat diet-induced obesity, insulin resistance and gut dysbiosis

Article ID	Journal	Published Year	Pages	File Type
5507860	Biochimica et Biophysica Acta (BBA) - General Subjects	2017	47 Pages	PDF

Abstract

DBZ may be used as a beneficial probiotic agent to improve HFD-induced obesity-related metabolic syndrome in obese individuals.

Keywords

BAT FAS TCM TZD PCoA Cpt1β HFD HOMA-IR PPARγ ORO LPL LDL-C QUICKI NMDS NCD T2D TLR NAFLD ACC TNFα LPS IL-6 IGTT DBZ SREBP1c UCP LefSe FATP RDA OTU PCA insulin tolerance test acetyl-CoA carboxylase fatty acid synthase linear discriminant analysis effect size interleukin-6 ITT epididymal white adipose tissue mesenteric white adipose tissue WAT, White adipose tissue brown adipose tissue Nonalcoholic fatty liver disease redundancy analysis Principal Coordinate Analysis Principal component analysis triglyceride tumor necrosis factor α thiazolidinediones Toll-like receptor Type 2 diabetes Oil red O high-fat diet normal chow diet traditional Chinese medicine Lipoprotein lipase lipopolysaccharide Obesity Insulin resistance non-metric multidimensional scaling Gut microbiota operational taxonomic unit Sterol regulatory element binding protein 1c Uncoupling protein Fatty acid transport protein WAT total cholesterol Low-density lipoprotein cholesterol Peroxisome proliferator-activated receptor gamma

Related Topics

Life Sciences Biochemistry, Genetics and Molecular Biology Biochemistry

DBZ is a putative PPARÎ³ agonist that prevents high fat diet-induced obesity, insulin resistance and gut dysbiosis

Authors

Pengfei Xu, Fan Hong, Jialin Wang, Jing Wang, Xia Zhao, Sheng Wang, Tingting Xue, Jingwei Xu, Xiaohui Zheng, Yonggong Zhai,